{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-24-000009","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.784785+00:00","generated_at":"2026-06-05T02:26:59.803526+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Xencor posts Phase 2 data for vudalimab (PD1 x CTLA-4) in mCRPC","bullets":["Additional clinical data from Phase 2 study of vudalimab monotherapy in metastatic castration-resistant prostate cancer posted on website.","Presentation includes vudalimab, a bispecific PD1 x CTLA-4 antibody, corporate overview.","No specific efficacy/safety figures provided in the filing; refer to full presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-24-000009","json":"https://secwatch.observer/filing/0001326732-24-000009.json","markdown":"https://secwatch.observer/filing/0001326732-24-000009.md","text":"https://secwatch.observer/filing/0001326732-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000009/0001326732-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000009/xncr-20240306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:26:59.803526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}